Literature DB >> 1370347

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

D Teitelbaum1, R Milo, R Arnon, M Sela.   

Abstract

Copolymer 1 (Cop 1) is a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis and has been proposed as a candidate drug for multiple sclerosis. Cop 1 is immunologically cross reactive with myelin basic protein (BP) and was shown to inhibit murine BP-specific T-cell lines of various H-2 restrictions. In the present study these findings were extended to include human T-cell lines. Cop 1 competitively inhibited the proliferative responses and interleukin 2 secretion of six BP-specific T-cell lines and 13 clones with several DR restrictions and epitope specificities. Conversely, BP inhibited--albeit to a lesser extent--the response of all the Cop 1-specific T-cell lines and clones, irrespective of their DR restrictions. Another random copolymer of tyrosine, glutamic acid, and alanine, denoted TGA, had no effect on these lines. Neither Cop 1 nor BP inhibited the response of lines and clones specific for purified protein derivative. Cop 1 and BP exerted their cross-inhibitory effects only in the presence of antigen-presenting cells. These results suggest that Cop 1 can compete with BP for the binding to human major histocompatibility complex molecules. In view of recent studies implicating BP reactivity in multiple sclerosis, these findings suggest a possible mechanism for the beneficial effect of Cop 1 in this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370347      PMCID: PMC48191          DOI: 10.1073/pnas.89.1.137

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex.

Authors:  H Hirshfeld; D Teitelbaum; R Arnon; M Sela
Journal:  FEBS Lett       Date:  1970-05-01       Impact factor: 4.124

Review 2.  T-cell recognition of myelin basic protein.

Authors:  K W Wucherpfennig; H L Weiner; D A Hafler
Journal:  Immunol Today       Date:  1991-08

3.  Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy.

Authors:  D C Wraith; D E Smilek; D J Mitchell; L Steinman; H O McDevitt
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

4.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

5.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

6.  The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

Review 7.  Peptide competition for antigen presentation.

Authors:  L Adorini; Z A Nagy
Journal:  Immunol Today       Date:  1990-01

8.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

Authors:  D Teitelbaum; C Webb; M Bree; A Meshorer; R Arnon; M Sela
Journal:  Clin Immunol Immunopathol       Date:  1974-11

9.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

10.  Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules.

Authors:  Y K Chou; M Vainiene; R Whitham; D Bourdette; C H Chou; G Hashim; H Offner; A A Vandenbark
Journal:  J Neurosci Res       Date:  1989-06       Impact factor: 4.164

View more
  25 in total

Review 1.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

2.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

Authors:  Jian Hong; Ningli Li; Xuejun Zhang; Biao Zheng; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

3.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

Authors:  R Aharoni; D Teitelbaum; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.

Authors:  William van der Touw; Kyeongah Kang; Yi Luan; Ge Ma; Sunny Mai; Lihui Qin; Guanglin Bian; Ruihua Zhang; Sathish Kumar Mungamuri; Hong-Ming Hu; Cheng Cheng Zhang; Stuart A Aaronson; Marc Feldmann; Wen-Chin Yang; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

Review 5.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

6.  Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).

Authors:  R Balabanov; D Lisak; T Beaumont; R P Lisak; P Dore-Duffy
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 7.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

8.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 9.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.